Characterization of the SARS-CoV-2 B.1.621 (Mu) variant-Reference-Cited by-同舟云学术

Characterization of the SARS-CoV-2 B.1.621 (Mu) variant

Published:2022-08-10 Issue:657 Volume:14 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Halfmann Peter J.¹^ORCID,Kuroda Makoto¹,Armbrust Tammy¹^ORCID,Theiler James²^ORCID,Balaram Ariane¹,Moreno Gage K.³^ORCID,Accola Molly A.⁴^ORCID,Iwatsuki-Horimoto Kiyoko⁵^ORCID,Valdez Riccardo⁶,Stoneman Emily⁷^ORCID,Braun Katarina¹^ORCID,Yamayoshi Seiya⁵^ORCID,Somsen Elizabeth³^ORCID,Baczenas John J.³⁸^ORCID,Mitamura Keiko⁹,Hagihara Masao¹⁰,Adachi Eisuke¹¹^ORCID,Koga Michiko¹²^ORCID,McLaughlin Matthew³^ORCID,Rehrauer William³⁴^ORCID,Imai Masaki⁵,Yamamoto Shinya¹²,Tsutsumi Takeya¹²,Saito Makoto¹²^ORCID,Friedrich Thomas C.¹⁸^ORCID,O’Connor Shelby L.³⁸^ORCID,O’Connor David H.³⁸^ORCID,Gordon Aubree¹³^ORCID,Korber Bette¹⁴¹⁵^ORCID,Kawaoka Yoshihiro¹⁵¹⁶^ORCID

Affiliation:

1. Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53711, USA.

2. Space Data Science and Systems, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.

3. Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI 53705, USA.

4. UW Health Clinical Laboratories, University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA.

5. Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, 108-8639 Tokyo, Japan.

6. Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.

7. Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.

8. Wisconsin National Primate Research Center, University of Wisconsin, Madison, WI 53715, USA.

9. Division of Infection Control, Eiju General Hospital, 110-8645 Tokyo, Japan.

10. Department of Hematology, Eiju General Hospital, 110-8645 Tokyo, Japan.

11. Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, 108-8639 Tokyo, Japan.

12. Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, 108-8639 Tokyo, Japan.

13. Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI 48109, USA.

14. Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.

15. New Mexico Consortium, Los Alamos, NM 87545, USA.

16. Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo 162-8655, Japan.

Abstract

The SARS-CoV-2 B.1.621 (Mu) variant emerged in January 2021 and was categorized as a variant of interest by the World Health Organization in August 2021. This designation prompted us to study the sensitivity of this variant to antibody neutralization. In a live virus neutralization assay with serum samples from individuals vaccinated with the Pfizer/BioNTech or Moderna mRNA vaccines, we measured neutralization antibody titers against B.1.621, an early isolate (spike 614D), and a variant of concern (B.1.351, Beta variant). We observed reduced neutralizing antibody titers against the B.1.621 variant (3.4- to 7-fold reduction, depending on the serum sample and time after the second vaccination) compared to the early isolate and a similar reduction when compared to B.1.351. Likewise, convalescent serum from hamsters previously infected with an early isolate neutralized B.1.621 to a lower degree. Despite this antibody titer reduction, hamsters could not be efficiently rechallenged with the B.1.621 variant, suggesting that the immune response to the first infection is adequate to provide protection against a subsequent infection with the B.1.621 variant.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference20 articles.

1. WHO “Tracking SARS-CoV-2 variants ” (World Health Organization who.int/activities/tracking-SARS-CoV-2-variants 2022).

2. Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2

3. A cluster of the new SARS‐CoV‐2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine

4. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

5. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Study of the COVID-19 Virus: A Review;The Open COVID Journal;2024-06-06

2. Challenges and opportunities in long COVID research;Immunity;2024-06

3. Implementing a provisional overarching intervention for COVID-19 monitoring and control in the Brazil-Colombia-Peru frontier;Frontiers in Public Health;2024-01-08

4. Exploring the Interplay of Mutations, Viral Stability, and Implications for Innovative Vaccination Strategies and Therapeutic Approaches Among Various SARS-CoV-2 Variants;2024-01-03

5. Low-Entropy Hydration Shells at the Spike RBD’s Binding Site May Reveal the Contagiousness of SARS-CoV-2 Variants;Biomolecules;2023-11-07